An analysis of previous studies indicates that allogeneic stem cell transplantation (SCT) (stem cells from a compatible donor) is associated with significant overall and relapse-free survival benefit among adult patients with intermediate- and poor-risk but not good-risk acute myeloid leukemia in first complete remission, compared with nonallogeneic SCT therapies, according to an article in the June 10 issue of JAMA.
Full article >>
Wednesday, June 10, 2009
Donor stem cell transplantation associated with survival benefit for patients with leukemia
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment